IL-17 an unlikely target for Crohn’s disease

Disappointing results from a phase II study suggests the inhibition of IL-17 may not be a potential target for treating Crohn’s disease. Writing in the American Journal of Gastroenterology the study authors noted that Interleukin (IL)-17 has an important role in immune-mediated diseases. Therapy targeting the IL-17 pathway had demonstrated encouraging results in other inflammatory diseases ...

Already a member?

Login to keep reading.

© 2021 the limbic